+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are studying bleximenib, a drug being evaluated for treating acute leukemia in this Phase 12 clinical trial. The study aims first to find the recommended dose of bleximenib that is safe and tolerable in adults and children with relapsed or refractory acute leukemia. The later phase will assess how well bleximenib works at that dose to fight leukemia. Participants in the early part of the study will receive increasing oral doses of bleximenib to identify safe levels. Then, more participants will take the recommended dose to confirm safety and learn about the drugs effects. In the Phase 2 part, participants will continue to take bleximenib orally at the recommended dose to evaluate its ability to induce remission and assess safety. During the study, participants will be monitored for side effects and response to treatment for up to nearly five years. Researchers will measure safety by tracking adverse events and dose-limiting toxicities in Phase 1, and remission rates in Phase 2. Blood tests, plasma drug levels, and assessments of leukemia response will be performed regularly. The study will also evaluate overall survival, event-free survival, and transfusion independence as important outcomes.

Age: 2Years +All GendersPhase 1Phase 2
102 locations
P

Actively Recruiting

Researchers are evaluating the combination of bleximenib with venetoclax VEN and azacitidine AZA compared to placebo with VEN and AZA alone for treating adults newly diagnosed with Acute Myeloid Leukemia AML who have specific gene mutations in NPM1 or KMT2A. This phase 3 randomized, double-blind study is designed for participants ineligible for intensive chemotherapy, aiming to understand how these treatments work in this population. Participants will receive treatment in 28-day cycles until disease progression or unacceptable side effects occur. One group will take oral bleximenib alongside oral venetoclax and intravenous or subcutaneous azacitidine, while the other group receives a placebo plus venetoclax and azacitidine. Treatment continues with regular cycles, and the study monitors effects over time. Throughout the study, participants will be assessed for response, including complete remission rates and overall survival, for up to more than four years. Researchers will also track event-free survival, duration and timing of remission, transfusion independence, adverse events, and blood levels of bleximenib. Safety and laboratory tests will be conducted regularly to monitor participant health and treatment effects.

Age: 18Years +All GendersPhase 3
270 locations
B

Actively Recruiting

Researchers are evaluating the addition of bleximenib, a drug that blocks a specific protein interaction in leukemia cells, to standard chemotherapy for adults with newly diagnosed acute myeloid leukemia AML who have mutations in the NPM1 or KMT2A genes. This phase 3, randomized, double-blind, placebo-controlled trial aims to see if bleximenib improves treatment outcomes compared to chemotherapy alone. Participants will be randomly assigned to one of three groups standard chemotherapy plus bleximenib with bleximenib maintenance, standard chemotherapy plus bleximenib with placebo maintenance, or standard chemotherapy plus placebo with placebo maintenance. Treatment continues until disease progression, unacceptable side effects, or other criteria require stopping. After the treatment phase, all participants will be followed observationally for up to four years to compare long-term outcomes. During the study, participants will receive standard chemotherapy drugs including cytarabine and daunorubicin or idarubicin, alongside the study drug or placebo. Researchers will monitor event-free survival as the primary outcome over up to four years and five months. Secondary outcomes include overall survival, remission rates, duration of remission, and the percentage undergoing stem cell transplantation, with follow-up extending up to nearly eight years. Safety and treatment effects will be closely observed throughout the study period.

Age: 18Years +All GendersPhase 3
98 locations